Mirum Pharmaceuticals, Inc.
LIVMARLI
Ultra-rare cholestatic pruritus
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for LIVMARLI in Ultra-rare cholestatic pruritus are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“LIVMARLI EXPAND Phase 3 study for pruritus in additional rare cholestatic conditions ... topline data expected in Q4 2026.”